YU44058B - Process for making derivatives of 2-amino-5-hydroxi-4-methylpyrimidine - Google Patents

Process for making derivatives of 2-amino-5-hydroxi-4-methylpyrimidine

Info

Publication number
YU44058B
YU44058B YU1695/84A YU169584A YU44058B YU 44058 B YU44058 B YU 44058B YU 1695/84 A YU1695/84 A YU 1695/84A YU 169584 A YU169584 A YU 169584A YU 44058 B YU44058 B YU 44058B
Authority
YU
Yugoslavia
Prior art keywords
amino
compounds
hydroxi
methylpyrimidine
useful
Prior art date
Application number
YU1695/84A
Other languages
English (en)
Other versions
YU169584A (en
Inventor
H Way
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of YU169584A publication Critical patent/YU169584A/xx
Publication of YU44058B publication Critical patent/YU44058B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
YU1695/84A 1983-10-03 1984-10-02 Process for making derivatives of 2-amino-5-hydroxi-4-methylpyrimidine YU44058B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/538,233 US4554276A (en) 1983-10-03 1983-10-03 2-Amino-5-hydroxy-4-methylpyrimidine derivatives

Publications (2)

Publication Number Publication Date
YU169584A YU169584A (en) 1987-02-28
YU44058B true YU44058B (en) 1990-02-28

Family

ID=24146051

Family Applications (1)

Application Number Title Priority Date Filing Date
YU1695/84A YU44058B (en) 1983-10-03 1984-10-02 Process for making derivatives of 2-amino-5-hydroxi-4-methylpyrimidine

Country Status (25)

Country Link
US (1) US4554276A (de)
EP (1) EP0138464B1 (de)
JP (1) JPS6094970A (de)
KR (1) KR860001818B1 (de)
AT (1) ATE47999T1 (de)
AU (1) AU548268B2 (de)
CA (1) CA1215985A (de)
DD (1) DD232698A5 (de)
DE (1) DE3480474D1 (de)
DK (1) DK162222C (de)
EG (1) EG16355A (de)
ES (1) ES8601924A1 (de)
FI (1) FI84479C (de)
GR (1) GR80512B (de)
HU (1) HU194186B (de)
IE (1) IE57633B1 (de)
IL (1) IL73104A (de)
NO (1) NO170883C (de)
NZ (1) NZ209740A (de)
PH (1) PH21038A (de)
PL (1) PL148590B1 (de)
PT (1) PT79278B (de)
SU (1) SU1342417A3 (de)
YU (1) YU44058B (de)
ZA (1) ZA847731B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711888A (en) 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
IE58373B1 (en) * 1986-06-18 1993-09-08 Bloomfield Frederick Jacob 5-Lipoxygenase pathway inhibitors
WO1989000423A1 (en) * 1987-07-09 1989-01-26 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
WO1989005295A1 (en) * 1987-12-02 1989-06-15 Pfizer Inc. Acyl derivatives of hydroxypyrimidines
US4910204A (en) * 1988-06-28 1990-03-20 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
DE68910288T2 (de) * 1988-12-14 1994-02-17 Pfizer Derivate von 5-Hydroxy- und 5-Methoxy-2-amino-pyrimidin als Inhibitoren der Interleukin-1-Produktion.
US5071852A (en) * 1988-12-14 1991-12-10 Pfizer Inc. Derivatives of 5-hydroxy and 5-methoxy 2-amino-pyrimidines as inhibitors of interleukin-1 production
US4940712A (en) * 1989-05-26 1990-07-10 Pfizer Inc. Derivatives of hydroxyprimidines as leukotriene synthesis inhibitors
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5177079A (en) * 1991-01-31 1993-01-05 Warner-Lambert Company 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5248682A (en) * 1991-01-31 1993-09-28 Warner-Lambert Company 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5220025A (en) * 1992-02-24 1993-06-15 Warner-Lambert Company 2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
WO1994001403A1 (en) * 1992-07-08 1994-01-20 Shell Internationale Research Maatschappij B.V. Piperidine derivatives
AU698313B2 (en) * 1994-03-14 1998-10-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
AU2001280445A1 (en) * 2000-06-23 2002-01-08 Vanderbilt University Novel chain-breaking antioxidants
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
WO2002098352A2 (en) * 2001-06-01 2002-12-12 Pozen Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004080979A1 (en) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives
DE102004054080A1 (de) * 2004-11-09 2006-05-11 Wella Ag Haut- oder Haarbehandlungsmittel mit Schutzeffekt
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
WO2009089134A1 (en) * 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
CA2736547C (en) * 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
CN116194102A (zh) 2020-07-15 2023-05-30 沙巴研究联合有限责任公司 用于治疗急性疼痛和降低胃灼热的严重程度和/或风险的包含布洛芬和法莫替丁的单位口服剂量组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000138A (en) * 1966-03-31 1976-12-28 Imperial Chemical Industries Limited Organic compounds and compositions containing them
US3932617A (en) * 1974-05-24 1976-01-13 The Upjohn Company Interferon induction
DE2814984A1 (de) * 1978-04-07 1979-10-18 Bayer Ag Pyrimidin(5)yl-(thiono)(thiol)- phosphor(phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
IN153791B (de) * 1979-03-10 1984-08-18 Soc D Etudes Prod Chimique
US4416885A (en) * 1979-11-02 1983-11-22 Huve Pierre M Use of isopropylaminopyrimidine in the chemotherapy of muscular dystrophy, myopathy and myotonia
OA07362A (fr) * 1980-10-27 1984-06-30 May & Baker Ltd Dérivés de la pyrimidine, leur procédé de préparation et les compositions les contenant.
US4435396A (en) * 1982-05-10 1984-03-06 Pfizer Inc. Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and process therefor

Also Published As

Publication number Publication date
FI843864A0 (fi) 1984-10-02
ATE47999T1 (de) 1989-12-15
GR80512B (en) 1985-02-01
US4554276A (en) 1985-11-19
IL73104A0 (en) 1984-12-31
ES536499A0 (es) 1985-11-16
KR850003402A (ko) 1985-06-17
ZA847731B (en) 1986-05-28
IE57633B1 (en) 1993-02-10
AU548268B2 (en) 1985-12-05
PL148590B1 (en) 1989-11-30
IE842494L (en) 1985-04-03
DK162222C (da) 1992-03-02
EP0138464B1 (de) 1989-11-15
IL73104A (en) 1987-12-20
PT79278B (en) 1986-11-18
DD232698A5 (de) 1986-02-05
YU169584A (en) 1987-02-28
CA1215985A (en) 1986-12-30
DK472184A (da) 1985-04-04
DE3480474D1 (de) 1989-12-21
PH21038A (en) 1987-07-03
JPH0528707B2 (de) 1993-04-27
JPS6094970A (ja) 1985-05-28
EP0138464A2 (de) 1985-04-24
NZ209740A (en) 1987-04-30
FI84479B (fi) 1991-08-30
HU194186B (en) 1988-01-28
NO170883B (no) 1992-09-14
FI84479C (fi) 1991-12-10
HUT35651A (en) 1985-07-29
DK162222B (da) 1991-09-30
ES8601924A1 (es) 1985-11-16
FI843864L (fi) 1985-04-04
NO843968L (no) 1985-04-09
AU3376884A (en) 1985-04-18
PL249833A1 (en) 1985-06-04
SU1342417A3 (ru) 1987-09-30
EP0138464A3 (en) 1986-08-20
EG16355A (en) 1987-04-30
NO170883C (no) 1992-12-23
PT79278A (en) 1984-10-01
KR860001818B1 (ko) 1986-10-24
DK472184D0 (da) 1984-10-02

Similar Documents

Publication Publication Date Title
EG16355A (en) Process for preparing of 2-amino-5-hydroxy-4-methylpyrimidine derivatives
NZ208529A (en) 2-pyrimidinyl-1-piperazine derivatives and pharmaceutical compositions
ES8404332A1 (es) Procedimiento para preparar acidos omega-(1,4,5-trifenilimidazol-2-iloxi)-alcanicos
DE3571982D1 (en) Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds
ES475035A1 (es) Un procedimiento para preparar derivados del acido cefalosporanico.
IL67969A0 (en) Novel crystal modifications of(+)-catechin,their production and pharmaceutical compositions containing them
ES8606347A1 (es) Un procedimiento para preparar derivados de purina
SE8405588D0 (sv) New compounds
ES8705382A1 (es) Un procedimiento para la preparacion de nuevos derivados de carbaciclina.
ES8802612A1 (es) Procedimiento para preparar derivados de benzisoselenazolilo
ES8300747A1 (es) Procedimiento para la preparacion de derivados de acido in- dolacetico
IL66192A (en) Albomycin derivatives,their production and pharmaceutical compositions containing them
GB1386027A (en) Esters of thienobenzopyrans and thiopyranobenzopyrans
ES8606375A1 (es) Un procedimiento para preparar un derivado de aminoprpilaminobleomicina